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Water molecules play a major role in the P450 catalytic cycle. Here, we locate the preferred water pathways
and their gating mechanisms for the human cytochrome P450 3A4 (CYP3A4) and elucidate the role of the
cytochrome P450 reductase (CPR) in turning on and activating these water channels. We perform explicit
solvent molecular dynamic simulations of CYP3A4, unbound and bound to two substrates, and with and
without the ﬂavin mononucleotide (FMN)-binding domain of CPR. We observe in/out passage of water
molecules via a water-speciﬁc and conserved channel (aqueduct) located between the active site and the
heme proximal side. We ﬁnd that the aqueduct gating mechanism is mediated by R375, the conserved arginine
that salt bridges with the heme 7-propionate. When R375 rotates, it opens the aqueduct and establishes a
connection between a cluster of active site water molecules network and the bulk solvent. The aqueduct
region overlaps with the CPR binding-site to CYP3A4. Indeed, we ﬁnd that when the FMN domain of CPR
binds to CYP3A4, the aqueduct fully opens up, thereby allowing a ﬂow of water molecules. The aqueduct’s
opening can permit proton transfer, shuttling the protons to the active site through ordered water molecules.
In addition, the expulsion of water molecules via the aqueduct contributes to substrate binding. As such, the
CPR binding has a function: it triggers the aqueduct’s opening and thereby enables a proton shuttle pathway,
which is needed for the dioxygen activation. This mechanism could be a general paradigm in P450s.
1. Introduction
Cytochrome P450 3A4 (CYP3A4) is a human mono-
oxygenase, heme-containing enzyme that belongs to the P450
protein superfamily. It oxidizes a variety of compounds1 and
can catalyze a wide spectrum of reactions, including hydroxy-
lation, epoxidation, and heteroatom dealkylations.2 CYP3A4 is
responsible for the oxidation of over 50% of orally taken drugs.3
The substrate oxidation is performed by the heme species, which
is located at the bottom of the active site, where it is covalently
ligated via an Fe-S bond to a conserved cysteine. The substrate
reaches this active site via the substrate access channels.4
The substrate oxidation process follows a well-deﬁned
catalytic cycle,5,6 shown in Figure 1.
In its low-spin ferric resting state (S ) 1/2), prior to substrate
entrance, the heme iron is coordinated to a water molecule.
Following substrate entrance (step 1) the coordinated water is
displaced, other water molecules leave the cavitiy as well, the
heme shifts to its high-spin state (S ) 5/2), and facilitates the
reduction (step 2) of the ferric center by NADPH-cytochrome
P450 reductase, denoted CPR.5,7 The so-formed ferrous complex,
which has an afﬁnity to O2, binds an O2 molecule and forms
the oxyferrous complex (step 3). Subsequent reduction (step
4), followed by two protonation events (steps 5 and 6), leads to
O-O bond cleavage and the formation of the active species,
called compound I (Cpd I, in Figure 1), which is a ferryl (FeIV)-
oxo-π porphyrin cation radical. Cpd I is thought to be
responsible for the bond activation in the substrate via hydrogen
abstraction (step 7), leading to substrate oxidation.5 Alterna-
tively, the protonation of the proximal oxygen of the ferric
hydroperoxide species (FeIII-OOH) species, generated in step
5 in Figure 1, will cause the release of hydrogen peroxide,
thereby uncoupling the oxygen consumption and substrate
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Figure 1. A typical P450 catalytic cycle. RH and ROH represent the
substrate and the product, respectively.
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in step 6, the catalytic cycle produces a water molecule that is
liberated during the O-O bond cleavage. The enzyme resumes
its resting state upon product release and the coordination of a
new water molecule to the heme iron.
Thus, if the substrate drives off the water molecules when it
enters the active site, what causes subsequently the protonation
steps? This must be caused by water molecules that shuttle the
protons, and as such, throughout the catalytic cycle, water
molecules must be trafﬁcking in and out of the active site. But
what are the water pathways that enable this trafﬁc, and what
is the trigger of this function? The central question in the present
paper is, how do we get a functional P450 catalytic cycle? We
apply molecular dynamics (MD) calculations and water-channel
characterizing techniques to understand the origins of the timing
of the water trafﬁcking and the reduction by the CPR.
Water Pathways in P450s. It was suggested that there exists
a solvent channel for controlling water passage from the bulk
solvent to the active site in the bacterial CYP102A1 (CYPBM3).10
This channel, with a radius of up to 2.2 Å, was deﬁned and
observed in many P450 isoforms,4 including the human
CYP3A4 (Figure 2).11,12 Taking into account conformational
changes, it is reasonable that substrates can pass through this
so-called solvent channel. It can also be assumed that water
molecules can pass through any substrate channel. Indeed, for
the human CYP2D6, another major drug metabolizing P450
isoform, it was proposed that this solvent channel also acts as
the main substrate access channel.13
This paper focuses on locating the distinct water channel, or
aqueduct (Figure 2), the physical mechanism whereby this
aqueduct is gated, and on the manner whereby the CPR activates
this function. The aqueduct, previously detected in bacterial
P450s, connects the active site with the protein surface14 and is
located between the 7-propionate side chain of the heme (Figures
2, 3A) and a conserved arginine, thus connecting the active site
through the proximal thiolate side of the heme toward the bulk
solvent.
Analysis of bacterial enzyme structures and their cavities led
Oprea et al.14 to propose a two-state model in which a conserved
arginine that forms a salt bridge with the negatively charged
heme 7-propionate ﬂips from its stable state to a less stable
rotamer. This rotamer opens the aqueduct, permitting water
passage from the active site to the bulk solvent. Although this
aqueduct has not been observed in all known P450 structures,
the similar fold15 of all P450 enzymes leads one to suspect that
this channel exists in most P450s, albeit largely in a closed,
stable state, hence, evading detection.
Strategy and Goals. A previous 4 ns MD simulation of an
unbound CYP3A416 showed that the active site was ﬁlled with
water; however, only a few ordered water molecules were
observed, and none of these were actually passing through the
aqueduct. To ascertain the function of the aqueduct and the
interplay of the CPR binding with this function, the present study
applies longer (20 ns) simulation times on two CYP3A4
conformers in the presence of two different substrates (diazepam
and testosterone, Figure 3B) and the ﬂavin mononucleotide
(FMN)-binding domain of CPR. Using MolAxis, a tool designed
to identify channels in macromolecules,17 we are able to gauge
the aqueduct and active site dimensions along the MD trajec-
tories. Our major ﬁnding is that the gating mechanism, which
follows Opera’s description,14 is, in fact, activated upon CPR
binding to CYP3A4, which opens the aqueduct and thereby
allows water passage. As a consequence, the bonding of the
CPR can regulates the protonation events in the cycle and leads
to a functional catalytic cycle.
2. Computational Methods
System setup: CYP3A4 structures (PDB18 codes: 1TQN and
2V0M) were used. Structure of the FMN-binding domain of
CPR was taken from PDB code 1BVY.19 Missing residues of
1TQN were modeled with InsightII (http://www.accelrys.com/
products/). For the 2V0M conformer, the missing residues were
modeled according to CR superimposition with 1TQN. For both
CYP3A4 structures, the pKa values were calculated with
MCCE20 (Supporting Information ﬁle, section 5). Hydrogen
atoms were added with CHARMM.21 Complexed inhibitors to
2V0M were removed. The structures were solvated in a box of
∼20 000 of explicit TIP3P22 water molecules, in addition to
crystallographic waters, resulting in an ∼14 Å padding between
the protein and the box facets. Chloride ions were added to
neutralize the system.
Force Field Parameters. Heme and protein parameters were
taken from CHARMM2223 and CHARMM2724 force ﬁelds,
respectively. To account for the C442 inﬂuence on the heme
atoms partial charges, we carried out a QM(B3LYP)/MM
optimization at the DFT level of theory with a sextet multiplicity
as the ground state, as studied before.25 The basis set used was
a LACVP basis set, which includes the highest s, p, and d shells;
the outermost core orbitals for iron; and a 6-31G basis set for
the rest of the heme and of the C442 ligand atoms. The Los
Alamos effective core potential for the iron was developed by
Hay et al.,26 along with matching basis sets. The heme Mulliken
charges were added to the force ﬁeld. The QM/MM calculation
used the ChemShell package.27 The diazepam and testosterone
Figure 2. CYP3A4 structure with various channels. The heme and
R375 are represented by VDW spheres and colored yellow and pink,
respectively. The protein is in a cartoon representation. The I helix is
purple; the BC loop is green; the F′G′ helixes is orange; the  1-sheet
is pink; the solvent channel is red; and the water channel (aqueduct) is
blue.
Figure 3. (A) The chemical structure of heme along with its 6- and
7-propionate moieties. (B) Chemical structures of testosterone (left)
and diazepam (right). Arrows indicate the hydroxylated carbon
positions.
Catalytic Cycle of Cytochrome P450 3A4 J. Phys. Chem. B, Vol. 114, No. 17, 2010 5965structures were taken from the Cambridge structural database
(http://www.ccdc.cam.ac.uk/products/csd/, codes DIZPAM10
and TESTOM01, respectively). The force ﬁeld parameters for
diazepam were taken from a previous study,28 and those of
testosterone were derived from a previously published CHARMM
force ﬁeld for cholesterol.29 Testosterone atomic partial charges
were calculated by a QM/MM optimization, as done with the
heme. The substrates were docked using the PatchDock30
software with their hydroxylated carbon (Figure 3B) facing the
heme’s iron. The lowest CHARMM energy docking solution
was used as a starting point for further MD simulation. The
CYP3A4-CPR complex was obtained by docking the CPR to
the CYP3A4 as follows: (a) We picked the 30 best geometrically
ﬁtted docking solutions obtained by the PatchDock software.
The docking procedure took into consideration previous knowl-
edge from mutations studies31 that served as constraints for the
docking. The docking solutions had to include interactions
between the CPR and K127, S131, T138, L142, K143, G140,
D428, R440, and L449 of CYP3A4. These residues correspond
to CYP2B4 residues that were shown experimentally to interact
with CYP3A4. (b) The ﬁltered solutions were minimized with
the CHARMM27 force ﬁeld. (c) The 10 lowest-energy docking
solutions were each structurally superimposed onto the
CYPBM3-CPR structure.19 The docking solution with the lowest
rmsd was chosen for further simulations. The FMN force ﬁeld
was obtained from the work of Freddolino et al.32 QM/MM
optimized coordinates and CHARMM topology ﬁles for the
heme and testosterone are available in the Supporting Informa-
tion ﬁle.
MD Procedures. The system energy in each run was initially
minimized with CHARMM. The enzyme was subjected to the
top 50 steps of minimization using the ABNR algorithm starting
with a force constant of 20 kcal/(mol Å2), followed by four
additional iterations, each one with half of the previous force
constant value used in previous minimization. The water
molecules were freely moveable along all minimization steps,
and the last iteration was with no harmonic constraint.
Subsequent procedures were performed using NAMD,33 and
all the system atoms had no constraint. The minimized system
was gradually heated from 0 to 310 K with a 20 K degree
increment and equilibrated for 50 ps. The simulations applied
a canonical NVT ensemble dynamics at 310 K witha1f stime
step. The Shake algorithm was applied to ﬁx all bond lengths
involving hydrogen atoms. A ﬁnal, nonbonded interaction cutoff
radius of 12 Å with a switching function starting from 10 Å
and nonbonded electrostatic interactions were calculated with
particle mesh Ewald summation. Snapshots were saved each
500 steps.
3. Results
Six MD simulations were performed: two substrate-free 20
ns simulations of CYP3A4 conformers 1TQN11 and 2V0M,34
denoted 3A4a and 3A4b respectively; 20 ns simulations with
diazepam and testosterone (Figure 3B) bound to the 3A4b
conformer, denoted 3A4b_DIA and 3A4b_TST respectively; and
two 10 ns simulations of the 3A4b_DIA and 3A4b_TST initial
structures complexed with the FMN-binding domain of CPR
denoted 3A4b_DIA_CPR and 3A4b_TST_CPR, respectively.
The average CYP3A4 CR rmsd and rms ﬂuctuations (RMSF)
along all trajectories do not exceed 1.7 ´ Å with low ﬂuctuations
(Supporting Information Figures S1A, S2). Major RMSF peaks
are related to known CYP3A4 ﬂexible regions that are missing
in several PDB ﬁles (Supporting Information Figure S2).12 In
the 3A4b_DIA_CPR and 3A4b_TST_CPR simulations, the CPR
CR rmsd rise up to 1.9 ´ Å, and the overall CPR structure does
not change (Supporting Information Figure S1B). Convergence
occurs relatively rapidly, and the global protein structures are
unchanged.
Water Pathways in CYP3A4. To assess the water mol-
ecules’ shuttling routes to and from the active site, we followed
all water molecules with a distance less than 4 Å from the heme
iron along the substrate-free simulations. In both 3A4a and 3A4b
simulations (free CYP3A4), we observed water passage through
several substrate access channels (Supporting Information Figure
S3). However, we focused our attention on water-speciﬁc
channels because most substrate channels are presumed to be
blocked for access when the substrate enters the cavity.
During the ﬁrst 10 ns of 3A4b MD, 10 water molecules
shuttled in and out of the CYP3A4 active site via the aqueduct
(the blue channel in Figure 2). This was not the case in the
3A4a simulation, in which all water molecules entered via
substrate channels. This could have been caused by the
conformational changes that have taken place due to the removal
of the two ketoconazole molecules which were present in the
initial structure of the 3A4b active site, or to coupling between
the ligand presence/entrance and the aqueduct opening, or to
both.
To evaluate the impact of the substrate inside the active site,
on the aqueduct opening and catalysis, we performed the
3A4b_DIA, 3A4b_TST, 3A4b_DIA_CPR, and 3A4b_TST_CPR
simulations. In the testosterone-bound simulation (3A4b_TST),
the aqueduct was closed during the entire simulation. In the
diazepam-bound simulation (3A4b_DIA), the aqueduct opened
at around 1 ns and then reclosed. However, when adding the
CPR to both substrate-bound simulations (3A4b_DIA_CPR and
3A4b_TST_CPR), the aqueduct was open during most of the
simulation time (70%), allowing water passage via the aqueduct.
This is a crucial result that highlights the role of the CPR as
the regulator of the timing of water trafﬁcking.
The Aqueduct Gating Mechanism. Water passage through
the aqueduct was observed in the 3A4b MD between 7.7 ns
and 9.8 ns. In the CPR containing simulations, the aqueduct
opened following 3 ns and remained open all the way to the
end of the simulations. The time frames during which water
molecules were observed to pass through the aqueduct cor-
respond to the moment when the heme 7-propionate-R375 salt
bridge was broken, reaching up to 7.5 Å of distance (Supporting
Information Figure S4). Furthermore, contact analysis of the
penetrating water molecules indicated that they entered in
proximity to the 7-propionate and R375. Unlike the cases with
bound CPR, in the 3A4a and 3A4b_TST simulations, the
7-propionate-R375 salt bridge was found to be stable with no
aqueduct opening. In 3A4b_DIA, the ﬁrst 2 ns demonstrated
ﬂuctuations in the salt bridge distance that allowed the opening
of the aqueduct for a short period in the presence of diazepam
(Supporting Information Figure S4). Out of the four arginines
that salt bridge the propionate moieties, only R375 manifested
ﬂexibility and weak interaction with its counterion (Supporting
Information Figure S5).
To deﬁne the mechanism whereby the aqueduct opens up,
we measured the torsion angles of the side chain (Supporting
Information S6) and backbone of R375 along the trajectories.
We did not observe much difference in the backbone torsion
angles; this is expected because R375 is located in the well-
organized  1 sheet. However, the R375 side chain torsion angles
present signiﬁcant ﬂuctuations in the trajectories when the
aqueduct was opened compared to time intervals when no
opening occurred (Supporting Information Figures S7-S9). The
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nidinium moiety shows the most signiﬁcant ﬂuctuations. These
ﬁndings conﬁrm the dynamics of the two-state model for the
conserved arginine in bacterial P450s.14 Figure 4 depicts these
two states in the case of CYP3A4 by superimposing the closed
and open states of the unbound 3A4b MD.
The 7- vs 6-Propionate as Gates. We further measured the
6- and 7-propionate rotatable dihedral angles along the trajec-
tories. The 7-propionate was found to be less stable than the
6-propionate (Supporting Information Figure S10). The 7-pro-
pionate dihedral angle ﬂuctuates much more along the trajec-
tories where the aqueduct was opened than in those where it
was closed. The general instability of the heme 7-propionate
observed here is supported by resonance Raman spectroscopy
on various P450s.35 However, we see a stronger relation between
the ﬂuctuations of the R375 side chain than that of the
7-propionate and the aqueduct opening. Since the R375 is
bulkier than the propionate moiety and more correlated to the
aqueduct opening, R375 is likely to be the main aqueduct gate-
keeper.
Aqueduct Structure and Conservation. The aqueduct
surface was calculated using MolAxis.17 The starting point for
the aqueduct search was 3 Å above the Fe atom. To perform
surface analysis, snapshots were taken at 10 ps intervals from
the 3A4a and 3A4b trajectories. The narrowest point calculated
in all aqueduct surfaces was at the 7-propionate-R375 salt bridge
(Supporting Information Figure S11). When the aqueduct was
fully open, its bottleneck radius reached a maximum of 1.49
Å, which is compatible with the radius of a water molecule
(Supporting Information Figure S12).
The putative aqueduct consists of R375 of the  1 sheet; G436,
S437, G438, P439, R440, N441, C442 of the heme binding
domain located in a loop connecting helixes L and K′; Y99,
T103, R105, N104 of the BC loop near the C terminal of the B
helix; and W126, K127 of the C helix. The CYP3A4 sequence
conservation was calculated with ConSeq36 using 500 unique
PSI-BLAST hits (Supporting Information Figure S13). Most of
the residues aligning the aqueduct, apart from S437, are highly
conserved. MolAxis detected the aqueduct in bacterial and
mammalian P450 species, including other human isoforms
(Figure 5).
Because the aqueduct appears to be conserved in the P450
family and there is only one fold for P450s in SCOP,37 we expect
that it exists in most P450s and relates to function.
The R375 position is occupied by a conserved positively
charged residue (usually Arg, but sometimes His or Lys) that
stabilizes the heme prosthetic group by salt bridging with the
heme 7-propionate. R375 corresponds to R299 of CYP101A1
(CYPcam), R293 of CYP107A1 (CYPeryF), and R319 of CYP108
(CYPterp) according to a multiple sequence alignment (based
on multiple structure alignment computed by STACCATO,38
Supporting Information Figure S14). In many PDB ﬁles, the
corresponding arginines show a metastable state. In CYPterp,
Hasemann et al.39 have shown that the R319 interaction with
7-propionate is mediated by ordered water molecules. In CYP55
(CYPnor), which is involved in the fungal reduction of NO to
N2O, the presence of a substrate in the active site is coupled to
the aqueduct opening and passage of water molecules between
R292 and the heme propionate (PDB code 1GEI40). Thus, not
only is the aqueduct conserved, but the gating mechanism
appears conserved, as well.
Water Occupancy in the CYP3A4 Active Site. To assess
their organization, we calculated the number of water molecules
in the active site and the number of hydrogen bonds they form.
Hydrogen bonds between water molecules were calculated using
thresholds previously determined for water molecules in clus-
ters.41 The number of active site water molecules and the
hydrogen bonding proﬁles are summarized in Supporting
Information Figure S15 (along with details of calculation). Along
the 3A4a and 3A4b simulations, there are 39 ( 15 and 40 (
14 active site water molecules, respectively. To determine the
level of ordering of the active site water molecules, we measured
how many hydrogen bonds each water molecule forms. An
ordered water molecule is considered to be one that forms at
least two hydrogen bonds with another water molecule or one
hydrogen bond with a water molecule and a hydrogen bond
with the enzyme. In the 3A4a and 3A4b simulations, only 10
( 2 hydrogen bonds between ordered active site water molecules
were observed. These results indicate that, generally, the active
site is full with water molecules, but few of them are ordered.
These results are in accord with the previous calculations of
Rydberg et al.16 on water behavior in various P450s. However,
the ordered water molecules found are mainly clustered in
proximity to the heme moiety and extend to the solvent channel
and to the aqueduct when opened (Figure 6).
There are also water molecules extending in the direction of
other substrate channels, but they are less ordered. In the
Figure 4. The gating mechanism of the aqueduct by R375. Superposi-
tion of two unbound 3A4b MD frames after 10 and 7130 ps. Note the
6.25 Å distance at the open state vis-a-vis 2.6-2.7 Å at the closed
state. The enzyme is colored orange; the heme and R375 of both frames
are in CPK.
Figure 5. Structural conservation of the aqueduct (drawn in blue) in
different P450s: (A) human CYP2C9, (B) mammalian CYP2B4, (C)
bacterial CYP107A1 (CYPeryF), and (D) bacterial CYP55 (CYPNOR).
The enzymes are drawn as cartoons; the heme and R375 are in red
VDW spheres.
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inside the active site. However, in the 3A4b_DIA simulation 5
( 1 ordered water molecules were present inside the active site,
despite the presence of diazepam. A testosterone molecule
positioned inside the active site resulted in almost complete
breakage of the ordered water molecules structures seen in the
unbound and in the diazepam-bound states. The addition of the
CPR to the substrate-bound states did not change the water
ordering in both substrate bound simulations.
The number count of the hydrogen bonds between water
molecules inside the active site represents a reliable physico-
chemical measure for assessing water order inside the active
site and may further point to the potential for proton transfer
by the water molecules.42 Experimental support for the presence
of ordered water molecules in the active site comes from the
CYP3A4 1TQN crystal structure.11 There, the active site is ﬁlled
with water molecules, and we observe at least 12 hydrogen
bonds between those molecules.
CYP3A4-CPR Interactions. We measured the close contacts
between CYP3A4 and CPR along the 3A4b_DIA_CPR and
3A4b_TST_CPR trajectories (Supporting Information Table S1).
We observed that the CPR side of the interface is generally
negatively charged, as seen previously,19 and the CYP3A4 side
is positively charged. CYP3A4 interacts strongly with CPR at
the heme binding loop (residues 428-446) close to the proximal
thiolate ligand of the heme and at the C helix. As shown in
Figure 7A, the S437 residue that is part of the heme binding
loop is bonded by hydrogen bonds (H-bonds) through its
backbone amine to carbonyl groups of the two components of
the salt bridge, the 7-propionate and R375. As shown in Figure
7B, upon CPR binding, in both CPR-containing simulations,
S437 switches partners and interacts with the CPR residues
N489 and M490. This interaction breaks the S437-7-propionate
H-bond while the interaction with R375 remains intact (Figure
7, Supporting Information Figure S16). Thus, the most notable
change in the vicinity of the 7-propionates was the S437 shifting
toward the CPR and pulling R375 along.
4. Discussion
Aqueduct Gating Regulation. Site-directed mutagenesis of
the CPR binding site in mammalian CYP2B4 identiﬁed nine
amino acids involved in CPR binding.31 R122 and K433 in
CYP2B4 belong to those amino acids, and they structurally
correspond to K127 and P439 in CYP3A4. These residues are
located at the entrance of the aqueduct (Figure 8A).
Superimposition of the CYP3A4 and the CYP102A1-CPR
complex structures (CR rmsd is low, 1.7 Å) revealed an overlap
between the CPR binding site and the aqueduct region. As such,
the CPR binding to P450s could control the opening of the
aqueduct. This hypothesis is, in fact, supported by the observa-
tion that the addition of the FMN-binding domain of CPR to
the CYP3A4 substrate-bound structures, which exhibited a
mainly closed aqueduct, resulted in an opened aqueduct during
75% of the trajectory (Figure 8B).
A cross-species analysis of the residues that salt bridge the
propionates moieties (Table S2) shows that the 7-propionate is
bound to fewer positive and sometimes less-protonated residues
(such as histidine), as compared to the 6-propionate. In CYP3A4,
the 7-propionate interacts with R375 and R105, but R105 also
interacts with the 6-propionate, thus weakening the salt bridge
with the 7-propionate. The 7-propionate is less stabilized by
electrostatic interactions than the 6-propionate, manifesting a
ﬂexible salt bridge with R375 that allows water passage through
it rather than via the 6-propionate. Because less-positive residues
interact with the 7-propionate, it is stabilized by H-bonding polar
groups, such as the S437 amine. The CPR binding (Figure 7)
interferes with these rather weak H-bonds and further destabi-
lizes the 7-propionate and the salt bridge, thereby opening the
aqueduct. Indeed, while in the absence of CPR binding, we did
not observe full aqueduct opening, the simulation in the presence
of CPR induced an aqueduct opening and complete salt bridge
breakage due to a further destabilization of the salt bridge
(Supporting Information Figure S4). This destabilization is
initiated by a strong electrostatic interaction between CYP3A4
Figure 6. Visualization of water molecules that potentially form a
H-bonded network connecting the active site and the mouths of the
aqueduct and solvent channels. For clarity, the hydrogen atoms of the
heme and diazepam are not shown. Snapshots are taken (A) after 8.9
ns of substrate-free MD in the 3A4b conformer and (B) after 900 ps of
the 3A4b_DIA MD.
Figure 7. S437-7-propionate and S437-R375 H-bonding. The
CYP3A4 is represented by orange cartoons; heme, R375, S437, and
M490 by CPK representation. Dotted lines represent H-bonds between
S437 backbone carbonyl, amine, and 7-propionate and R375. (A) Initial
structure of the 3A4b_TST_CPR. (B) Snapshot after 5 ns of the
3A4b_TST_CPR MD. Bolded is part of the 428-446 loop.
Figure 8. CYP3A4-CPR interaction. (A) A general overview of the
CYP3A4-CPR complex. The proteins are represented by cartoons, and
the heme and R375, by yellow VDW spheres. CYP3A4 is in blue, and
CPR is in red. The aqueduct surface is colored green. K127 and P439
are represented by gray VDW spheres. (B) Aqueduct opening by
interaction between CYP3A4 and CPR after 5 ns of MD. CYP3A4 is
represented by blue ribbons, and CPR, by red ribbons. Testosterone,
heme, R375, and FMN are represented by balls and sticks, and the
water, by VDW spheres. For clarity, testosterone and heme are shown
without hydrogens.
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the case of CYP3A4-S437, which moves away from the
7-propionate toward the CPR. This H-bond switching is
considered to be the apparent physical mechanism for the
aqueduct open-close states and the resultant weakening of the
already labile salt bridge interaction.
The distinction between the 6- and 7-propionates has been
demonstrated in recent studies, using reconstituted bacterial
CYP101A1 in which either the 6- or the 7-propionate was
replaced by a methyl group.43,44 Thus, the 6-propionate replace-
ment resulted in an inactive P420 species as a result of facile
protonation of the C357 (corresponding to C442 in CYP3A4)
thiolate. In contrast, the removal of the 7-propionate arm did
not adversely affect the hydroxylation reaction of camphor, and
the reaction remained well-coupled with oxidation of NADH.
These results are in agreement with the observation during our
MD studies that the two propionates behave entirely differently.
The 6-propionate forms tight electrostatic interactions with the
enzyme, and this intimate interaction between the 6-propionate
and the enzyme was found to be essential for the P450 activity.
On the other hand, the 7-propionate arm acts as a water gate,
and its removal by Hayashi et al.42 has generated an open
aqueduct throughout the catalytic cycle, thereby permitting free
water ﬂow out of and into the active site.
A Summary of the Aqueduct Roles Related to P450
Catalysis. Our above ﬁndings on the interplay between the
aqueduct opening/closure and the substrate and CPR binding
events lead to the conclusion that the aqueduct-substrate-CPR
combination makes the catalytic cycle in Figure 1 functional.
Thus, upon substrate binding, the water molecules are displaced
from the active site, and the aqueduct closes the gate. In the
3A4b simulation, seven water molecules escaped the active site
through the aqueduct, and in the simulations with testosterone
inside, the active site was, in fact, dehydrated. Thus, the
aqueduct enables the desolvation effect and thereby assists
substrate binding via increased entropy and a decrease in the
binding free energy.5,45 This water departure has another
important effect, since it makes the heme a better electron
acceptor and, hence, more easily reducible. However, this also
leaves the active site without a proton shuttle pathway that is
necessary for the activation of the O-O bond (Figure 1). Upon
CPR binding, the aqueduct opens again; this permits a ﬂow of
water molecules, with a consequent formation of a proton shuttle
pathway connecting the active site to the proximal side of the
heme. As such, the binding of CPR acts as an internal timer of
the cycle; it initiates the electron transfers to the heme, and by
permitting water re-entry, it couples the proton shuttle to the
reduction events, which is in line with the experimental
observation of a solvent kinetic isotope effect during reduction.46
Shuttling protons in and out of enzymes active sites has
already been shown to be water-mediated.47,48 Our MD simula-
tions reveal two different structures of ordered water molecules
inside the active site. One extends from the active site to the
aqueduct when opened (Figure 6A, B, lower right), and another
extends in the general direction of the solvent channel (Figure
6A, B, upper left) involving E308 and T309 (corresponding to
residues D251 and T252 in the bacterial CYP101A1 (CYPcam)).
This threonine residue promotes the second protonation of the
distal oxygen of the iron peroxo species, thereby forming Cpd
I.49 Previous experimental studies with CYP101A149,50 have
already detected ordered structures of water molecules through
the solvent channel’s interacting with T252 and forming part
of a proton relay system to the iron-linked dioxygen. Zhao et
al.51 observed in bacterial CYP158A2 a cluster of ordered water
molecules connecting the active site to bulk solvent that may
participate in proton transfer and that this cluster does not
involve the conserved threonine. They suggested two classes
of P450s based on their proton transfer type: one using the
conserved threonine and another using substrate hydroxyl groups
inside the active site to stabilize the water pathway for proton
supply. Their results support the possibility that ordered water
molecule structures could coexist in the presence of substrates
as seen in our diazepam simulations.
A strong experimental support for our observation that the
aqueduct is relevant to the catalytic cycle comes from the study
of Hayashi et al.,44 in which the 7-propionate was replaced with
a methyl group. The authors showed that the 7-propionate of
CYPcam serves as a gate for regulating water access to the P450
active site. Not only was the aqueduct open along the entire
catalytic cycle of camphor hydroxylation, but also the water
molecules present in the aqueduct and active site were engaged
in a network of hydrogen bonds connecting the active site to
bulk water.
Furthermore, Bridges et al.31 demonstrated by site-directed
mutagenesis that the binding sites on the proximal surface of
CYP2B4 for CPR and cytochrome b5 partially overlap. This
overlap, localized at the aqueduct region, forms the basis for
competitive inhibition between CPR and cytochrome b5.52 In
addition, cytochrome b5, which could potentially supply the
second electron in the catalytic cycle (like CPR) and which was
shown to affect CYP3A4,53 induced a higher catalytic activity
as compared to the CYP2B4-CPR complex.52 The authors
explain the observed increase in the rate of product formation
by a more rapid second protonation of the hydroperoxo
intermediate (step 6 in Figure 1) to Cpd I. The overlap between
the cytochrome b5 binding site to P450s and the aqueduct region
is speculated to result in a signiﬁcant aqueduct opening upon
cytochrome b5’s binding. Subsequently, this opening could lead
to a faster second protonation and a higher catalytic activity, as
observed in CYP2B4.52
In cytochrome c oxidase, which cleaves oxygen and is needed
for cell respiration in aerobic organisms, it was shown that a
conserved arginine-heme propionate salt bridge exhibits revers-
ible thermal opening.48 This ion pair serves as a speciﬁc gate
for water passage and was found experimentally to be involved
in the proton-pumping mechanism.
In the only available structure of a P450 enzyme (CYP102A1)
in complex with the FMN-binding domain of CPR,19 the
aqueduct is open with a cluster of ordered water molecules
connecting the active site to the proximal heme thiolate ligand.
There is also experimental evidence that CPR binding leads to
allosteric changes in the substrate orientation inside the bacterial
and human P450s active site and inﬂuences the heme iron spin
state.54,55 This allosteric effect is expected to occur through side
chain or even secondary structure movements in the vicinity of
the aqueduct entrance that can lead to its opening. Therefore, it
is possible that our proposed involvement of the aqueduct and
propionate salt bridge in proton transfer is more general and is
shared by other P450 isoforms and heme-containing oxygenases
apart from the P450 family.
Acknowledgment. This project has been funded in whole or
in part by federal funds from the National Cancer Institute, National
Institutes of Health, under Contract No. HHSN261200800001E.
The content of this publication does not necessarily reﬂect the
views or policies of the Department of Health and Human
Services, nor does mention of trade names, commercial products,
or organizations imply endorsement by the U.S. Government.
This research was supported (in part) by the Intramural Research
Catalytic Cycle of Cytochrome P450 3A4 J. Phys. Chem. B, Vol. 114, No. 17, 2010 5969Program of the National Institutes of Health, National Cancer
Institute, Center for Cancer Research. The research at the HU
was supported in parts by ISF (53/09) and DIP (DIP-F.7.1)
grants to S.S. This study utilized the high-performance com-
putational capabilities of the Biowulf PC/Linux cluster at the
National Institutes of Health, Bethesda, MD (http://biowulf.
nih.gov).
Supporting Information Available: QM/MM optimized
coordinates, CHARMM topology ﬁles for the heme and
substartes, MD proﬁles, and other ﬁgures are available in the
Supporting Information ﬁle. This material is available free of
charge via the Internet at http://pubs.acs.org.
References and Notes
(1) Guengerich, F. P. In In cytochrome P450: Structure, Mechanism
and Biochemistry, 3rd ed.; Ortiz de Montellano, P. R., Ed.; Plenum Press:
New York, 2005; pp 377-531.
(2) Sono, M.; Roach, M. P.; Coulter, E. D.; Dawson, J. H. Chem. ReV.
1996, 96, 2841–2888.
(3) Wrighton, S. A.; Schuetz, E. G.; Thummel, K. E.; Shen, D. D.;
Korzekwa, K. R.; Watkins, P. B. Drug Metab. ReV. 2000, 32, 339–361.
(4) Cojocaru, V.; Winn, P. J.; Wade, R. C. Biochim. Biophys. Acta
2007, 1770, 390–401.
(5) Shaik, S.; Kumar, D.; de Visser, S. P.; Altun, A.; Thiel, W. Chem.
ReV. 2005, 105, 2279–2328.
(6) Davydov, R.; Makris, T. M.; Kofman, V.; Werst, D. E.; Sligar,
S. G.; Hoffman, B. M. J. Am. Chem. Soc. 2001, 123, 1403–1415.
(7) Harris, D.; Loew, G. J. Am. Chem. Soc. 1993, 115, 8775–8779.
(8) Loida, P. J.; Sligar, S. G. Biochemistry 1993, 32, 11530–11538.
(9) Altarsha, M.; Benighaus, T.; Kumar, D.; Thiel, W. J. Am. Chem.
Soc. 2009, 131, 4755–4763.
(10) Haines, D. C.; Tomchick, D. R.; Machius, M.; Peterson, J. A.
Biochemistry 2001, 40, 13456–13465.
(11) Yano, J. K.; Wester, M. R.; Schoch, G. A.; Grifﬁn, K. J.; Stout,
C. D.; Johnson, E. F. J. Biol. Chem. 2004, 279, 38091–38094.
(12) Williams, P. A.; Cosme, J.; Vinkovic, D. M.; Ward, A.; Angove,
H. C.; Day, P. J.; Vonrhein, C.; Tickle, I. J.; Jhoti, H. Science 2004, 305,
683–686.
(13) Rowland, P.; Blaney, F. E.; Smyth, M. G.; Jones, J. J.; Leydon,
V. R.; Oxbrow, A. K.; Lewis, C. J.; Tennant, M. G.; Modi, S.; Eggleston,
D. S.; Chenery, R. J.; Bridges, A. M. J. Biol. Chem. 2006, 281, 7614–
7622.
(14) Oprea, T. I.; Hummer, G.; Garcia, A. E. Proc. Natl. Acad. Sci.
U.S.A. 1997, 94, 2133–2138.
(15) Poulos, T. L. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 13121–13122.
(16) Rydberg, P.; Rod, T. H.; Olsen, L.; Ryde, U. J. Phys. Chem. B
2007, 111, 5445–5457.
(17) Yaffe, E.; Fishelovitch, D.; Wolfson, H. J.; Halperin, D.; Nussinov,
R. Nucleic Acids Res. 2008, 36, W210–215.
(18) Bernstein, F. C.; Koetzle, T. F.; Williams, G. J.; Meyer, E. F., Jr.;
Brice, M. D.; Rodgers, J. R.; Kennard, O.; Shimanouchi, T.; Tasumi, M.
Eur. J. Biochem. 1977, 80, 319–324.
(19) Sevrioukova, I. F.; Li, H.; Zhang, H.; Peterson, J. A.; Poulos, T. L.
Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 1863–1868.
(20) Georgescu, R. E.; Alexov, E. G.; Gunner, M. R. Biophys. J. 2002,
83, 1731–1748.
(21) Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D.; States, D. J.;
Swaminathan, S.; Karplus, M. J. Comput. Chem. 1983, 4, 187–217.
(22) Jorgensen, W. L.; Chandrasekhar, J.; Madura, J. D.; Impey, R. W.;
Klein, M. L. J. Chem. Phys. 1983, 79, 926–935.
(23) MacKerell, A. D., Jr.; Bashford, D.; Bellott, M.; Dunbrack, R. L.,
Jr,; Evanseck, J. D.; Field, M. J.; Fischer, S.; Gao, J.; Guo, H.; Ha, S.;
Joseph-McCarthy, D.; Kuchnir, L.; Kuczera, K.; Lau, F. T. K.; Mattos, C.;
Michnick, S.; Ngo, T.; Nguyen, D. T.; Prodhom, B.; Reiher, W.E., III; Roux,
B.; Schlenkrich, M.; Smith, J. C.; Stote, R.; Straub, J.; Watanabe, M.;
Wiorkiewicz-Kuczera, J.; Yin, D.; Karplus, M. J. Phys. Chem. B 1998,
102, 3586–3616.
(24) Mackerell, A. D., Jr.; Feig, M.; Brooks, C. L., 3rd. J. Comput. Chem.
2004, 25, 1400–1415.
(25) Altun, A.; Thiel, W. J. Phys. Chem. B 2005, 109, 1268–1280.
(26) Hay, P. J. W., W. R. J. Chem. Phys. 1985, 82, 299–310.
(27) Sherwood, P.; de Vries, A. H.; Guest, M. F.; Schreckenbach, G.;
Catlow, C. R. A.; French, S. A.; Sokol, A. A.; Bromley, S. T.; Thiel, W.;
Turner, A. J.; Billeter, S.; Terstegen, F.; Thiel, S.; Kendrick, J.; Rogers,
S. C.; Casci, J.; Watson, M.; King, F.; Karlsen, E.; Sjovoll, M.; Fahmi, A.;
Schafer, A.; Lennartz, C. J. Mol. Struct. Theochem. 2003, 632, 1–28.
(28) Fishelovitch, D.; Hazan, C.; Shaik, S.; Wolfson, H. J.; Nussinov,
R. J. Am. Chem. Soc. 2007, 129, 1602–1611.
(29) Cournia, Z.; Smith, J. C.; Ullmann, G. M. J. Comput. Chem. 2005,
26, 1383–1399.
(30) Schneidman-Duhovny, D.; Inbar, Y.; Nussinov, R.; Wolfson, H. J.
Nucleic Acids Res. 2005, 33, W363–367.
(31) Bridges, A.; Gruenke, L.; Chang, Y. T.; Vakser, I. A.; Loew, G.;
Waskell, L. J. Biol. Chem. 1998, 273, 17036–17049.
(32) Freddolino, P. L.; Dittrich, M.; Schulten, K. Biophys. J. 2006, 91,
3630–3639.
(33) Phillips, J. C.; Braun, R.; Wang, W.; Gumbart, J.; Tajkhorshid, E.;
Villa, E.; Chipot, C.; Skeel, R. D.; Kale, L.; Schulten, K. J. Comput. Chem.
2005, 26, 1781–1802.
(34) Ekroos, M.; Sjogren, T. Proc. Natl. Acad. Sci. U.S.A. 2006, 103,
13682–13687.
(35) Hudecek, J.; Anzenbacherova, E.; Anzenbacher, P.; Munro, A. W.;
Hildebrandt, P. Arch. Biochem. Biophys. 2000, 383, 70–78.
(36) Berezin, C.; Glaser, F.; Rosenberg, J.; Paz, I.; Pupko, T.; Fariselli,
P.; Casadio, R.; Ben-Tal, N. Bioinformatics 2004, 20, 1322–1324.
(37) Murzin, A. G.; Brenner, S. E.; Hubbard, T.; Chothia, C. J. Mol.
Biol. 1995, 247, 536–540.
(38) Shatsky, M.; Nussinov, R.; Wolfson, H. J. Proteins 2006, 62, 209–
217.
(39) Hasemann, C. A.; Ravichandran, K. G.; Peterson, J. A.; Deisenhofer,
J. J. Mol. Biol. 1994, 236, 1169–1185.
(40) Lee, D. S.; Park, S. Y.; Yamane, K.; Obayashi, E.; Hori, H.; Shiro,
Y. Biochemistry 2001, 40, 2669–2677.
(41) Khan, A. J. Chem. Phys. 1999, 110, 11884–11889.
(42) Tuckerman, M.; Laasonen, K.; Sprik, M.; Parrinello, M. J. Phys.
Chem. 1995, 5749–5752.
(43) Harada, K.; Sakurai, K.; Ikemura, K.; Ogura, T.; Hirota, S.;
Shimada, H.; Hayashi, T. J. Am. Chem. Soc. 2008, 130, 432–433.
(44) Hayashi, T.; Harada, K.; Sakurai, K.; Shimada, H.; Hirota, S. J. Am.
Chem. Soc. 2009, 131, 1398–1400.
(45) Lewis, D. F.; Jacobs, M. N.; Dickins, M. Drug DiscoVery Today
2004, 9, 530–537.
(46) Vidakovic, M.; Sligar, S. G.; Li, H.; Poulos, T. L. Biochemistry
1998, 37, 9211–9219.
(47) Zhang, X.; Bruice, T. C. Biochemistry 2007, 46, 14838–14844.
(48) Wikstrom, M.; Ribacka, C.; Molin, M.; Laakkonen, L.; Verkhovsky,
M.; Puustinen, A. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 10478–10481.
(49) Nagano, S.; Poulos, T. L. J. Biol. Chem. 2005, 280, 31659–31663.
(50) Schlichting, I.; Berendzen, J.; Chu, K.; Stock, A. M.; Maves, S. A.;
Benson, D. E.; Sweet, R. M.; Ringe, D.; Petsko, G. A.; Sligar, S. G. Science
2000, 287, 1615–1622.
(51) Zhao, B.; Guengerich, F. P.; Voehler, M.; Waterman, M. R. J. Biol.
Chem. 2005, 280, 42188–42197.
(52) Zhang, H.; Im, S. C.; Waskell, L. J. Biol. Chem. 2007, 282, 29766–
29776.
(53) Yamazaki, H.; Nakajima, M.; Nakamura, M.; Asahi, S.; Shimada,
N.; Gillam, E. M.; Guengerich, F. P.; Shimada, T.; Yokoi, T. Drug Metab.
Dispos. 1999, 27, 999–1004.
(54) Modi, S.; Sutcliffe, M. J.; Primrose, W. U.; Lian, L. Y.; Roberts,
G. C. Nat. Struct. Biol. 1996, 3, 414–417.
(55) Modi, S.; Gilham, D. E.; Sutcliffe, M. J.; Lian, L. Y.; Primrose,
W. U.; Wolf, C. R.; Roberts, G. C. Biochemistry 1997, 36, 4461–4470.
JP101894K
5970 J. Phys. Chem. B, Vol. 114, No. 17, 2010 Fishelovitch et al.